Teva Pharmaceutical
Industries Ltd. TEVA and Active Biotech
announced today that both companies remain committed to the NERVENTRA^®
(laquinimod) clinical development program for multiple sclerosis (MS)
following the announcement of a negative opinion for the treatment of
relapsing-remitting multiple sclerosis (RRMS) by the Committee for Medicinal
Products for Human Use (CHMP) of the European Medicines Agency (EMA).
The CHMP has concluded that the risk-benefit profile of NERVENTRA is not
favorable at this time. In accordance with European regulations, Teva and
Active Biotech intend to request a re-examination of the CHMP opinion. Teva
and Active Biotech are focusing on evaluating the CHMP's review and will
continue to liaise closely with the EMA in working to make NERVENTRA available
as a new treatment option for patients with RRMS in Europe.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Posted In: News
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in